Business Context and Reporting Period
Passage Bio, Inc. filed a Form 8-K dated February 24, 2023, under Item 7.01, Regulation FD Disclosure. The company announced a scientific presentation at the 19th Annual WORLD Symposium Conference concerning interim data from the Imagine-1 Phase 1/2 clinical trial of PBGM01, a gene therapy for GM1 gangliosidosis.
Financial and Operating Metrics
This filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other financial metrics. The filing text also does not provide clear clinical-trial numerical results; those materials are included in Exhibits 99.1 and 99.2 but were not provided in the source text.
Material Changes Versus Prior Period
No financial or operational period-over-period comparison is disclosed. The material update is the release of additional interim clinical data relating to PBGM01 and the Imagine-1 trial.
Guidance, Outlook, Risks, and Unusual Items
- The filing does not provide financial guidance or a quantified corporate outlook.
- The announced information relates to an early-stage clinical program and remains subject to clinical, regulatory, development, manufacturing, and commercialization risks.
- The press release and presentation were furnished under Item 7.01 and are not deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference into other filings, except where expressly stated.
- Exhibits 99.1 and 99.2 contain the press release and WORLD presentation, respectively, and may include the underlying interim clinical data not reproduced in the filing text.
Key Facts to Verify
- Review Exhibit 99.1 for the company’s detailed interpretation of the Imagine-1 interim results.
- Review Exhibit 99.2 for patient numbers, dosing, efficacy, biomarker, safety, and follow-up data.
- Verify the clinical-development and regulatory status of PBGM01 following the presentation.
- Consult the company’s latest periodic filings for cash runway, liquidity, operating losses, financing needs, and other financial information not included in this 8-K.